Regarding disease control as a predictive factor, reductions in GH and IGF-1 in patients with newly diagnosed acromegaly who were treated with octreotide for 6 months without ADM were shown to correlate with change in HbA1c levels [33]; however, a similar association in patients treated with pasireotide has not yet been studied. This evidence concerns the gene IGF1 and acromegaly.